The psychonaut comic brings a two-part, art-drenched special to life at Meow Wolf Denver. Here’s what to know about TRIPS, why he calls LSD “boring,” and what DMV audiences should watch for.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

A tense exchange at Psychedelic Culture put ethics of research in conflict zones under a microscope—raising questions for psychedelic science, patient access, and the DMV.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

How the Bulletproof founder views biological optimization as a gateway to deeper self-awareness, integration, and spiritual growth.

MAPS linked with New Jersey’s HoneyProjects to bring education into a dispensary setting—its first retail cannabis partnership in 40 years—and it could reshape how patients learn.

At Chacruna’s Psychedelic Culture Conference, protesters challenged MAPS over work in Israel, igniting a raw debate on ethics, equity, and community accountability.

Resilient Pharmaceuticals submits a renewed application for MDMA-assisted PTSD therapy, seeking FDA approval without a fresh Phase 3 trial.